BMS Wins Competition For Novel Checkpoint Inhibitors With Relatlimab Approval

 
• By Joseph Haas
  
New cancer discovery
Bristol gets first approval for new checkpoint immunotherapy, LAG-3 • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip